$TNGX has generated 14 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on July 24, 2025. Adam Feuerstein and Jacob Plieth each contributed 7 mentions, making them the only voices discussing the stock in the archive. Discussion centered on biotech sector developments, with the most recent activity occurring on June 12, 2026.

Recent mentions have focused on $TNGX within the context of broader biotech industry developments. Jacob Plieth noted a $600 million secondary offering by $TNGX in early June 2026 as part of a notably active week in biotech financings and acquisitions. Adam Feuerstein referenced $TNGX in connection with 'synthetic lethality' and potential M&A activity in the biotech space, and separately discussed the stock's PRMT5 inhibitor program in relation to comparable programs at other companies.